AU2002237646A1 - Production and use of proteins producing an altered immunogenic response - Google Patents

Production and use of proteins producing an altered immunogenic response

Info

Publication number
AU2002237646A1
AU2002237646A1 AU2002237646A AU3764602A AU2002237646A1 AU 2002237646 A1 AU2002237646 A1 AU 2002237646A1 AU 2002237646 A AU2002237646 A AU 2002237646A AU 3764602 A AU3764602 A AU 3764602A AU 2002237646 A1 AU2002237646 A1 AU 2002237646A1
Authority
AU
Australia
Prior art keywords
production
immunogenic response
altered immunogenic
proteins producing
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002237646A
Inventor
David A. Estell
Fiona A. Harding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/677,822 external-priority patent/US6936249B1/en
Application filed by Genencor International Inc filed Critical Genencor International Inc
Publication of AU2002237646A1 publication Critical patent/AU2002237646A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Abstract

The present invention relates to a novel methods and compositions for producing hyper and hypo allergenic compositions. Specifically, the present invention comprises neutralizing or reducing the ability of T-cells to recognize epitopes and thus prevent sensitization of an individual to the protein. Alternatively, T-cell epitopes are mutated to produce increased immunogenic reactions.
AU2002237646A 2000-10-02 2001-09-26 Production and use of proteins producing an altered immunogenic response Abandoned AU2002237646A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/677,822 2000-10-02
US09/677,822 US6936249B1 (en) 1998-04-15 2000-10-02 Proteins producing an altered immunogenic response and methods of making and using the same
US09/768,080 US6897049B1 (en) 1998-04-15 2001-01-23 Proteins producing an altered immunogenic response and methods of making and using the same
US09/768,080 2001-01-23
PCT/US2001/030062 WO2002040997A2 (en) 2000-10-02 2001-09-26 Production and use of proteins producing an altered immunogenic response

Publications (1)

Publication Number Publication Date
AU2002237646A1 true AU2002237646A1 (en) 2002-05-27

Family

ID=27101907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002237646A Abandoned AU2002237646A1 (en) 2000-10-02 2001-09-26 Production and use of proteins producing an altered immunogenic response

Country Status (7)

Country Link
EP (1) EP1469721B1 (en)
JP (1) JP5126761B2 (en)
AT (1) ATE504205T1 (en)
AU (1) AU2002237646A1 (en)
CA (1) CA2424720C (en)
DE (1) DE60144399D1 (en)
WO (1) WO2002040997A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2311458C2 (en) 2001-03-23 2007-11-27 Джененкор Интернэшнл, Инк. Proteins causing alternated immunogenic response and methods for their preparing and using
PL371675A1 (en) * 2002-06-11 2005-06-27 Merck Patent Gmbh Method for mapping and eliminating t-cell epitopes
EP1740952A2 (en) * 2004-04-26 2007-01-10 Genencor International, Inc. Population based prediction methods for immune response determinations and methods for verifying immunological response data
EP2589651A3 (en) 2008-11-11 2013-08-28 Danisco US Inc. Compositions and methods comprising serine protease variants
CN102064161B (en) * 2010-11-12 2013-09-04 嘉兴斯达微电子有限公司 Optimized power package structure of intelligent power module
GB2499180A (en) * 2011-09-08 2013-08-14 Alcyomics Ltd Method of identifying sensitizers or allergens using measurements of T-cell proliferation and/or IFN Gamma
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
SG30639G (en) 1986-04-30 1995-09-01 Genencor Int Non-human carbonyl hydrolase mutants DNA sequences and vectors encoding same and hosts transformed with said vectors
US5470560A (en) * 1987-01-20 1995-11-28 Genentech, Inc. Method for evaluating immunogenicity
DE69130113T2 (en) * 1990-12-05 1999-05-12 Novo Nordisk As PROTEINS WITH CHANGED EPITOPES AND METHOD FOR THE PRODUCTION THEREOF
WO1999006061A1 (en) * 1997-07-29 1999-02-11 The Administrators Of The Tulane Educational Fund Prediction, detection, and design of t cell epitopes
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
CN1202128C (en) * 1998-12-08 2005-05-18 拜奥威神有限公司 Method for reducing immunogenicity of proteins

Also Published As

Publication number Publication date
EP1469721A2 (en) 2004-10-27
WO2002040997A9 (en) 2002-07-25
EP1469721B1 (en) 2011-04-06
CA2424720C (en) 2012-04-03
WO2002040997A3 (en) 2004-08-12
WO2002040997A2 (en) 2002-05-23
DE60144399D1 (en) 2011-05-19
JP2004528013A (en) 2004-09-16
CA2424720A1 (en) 2002-05-23
ATE504205T1 (en) 2011-04-15
JP5126761B2 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
WO2001059130A3 (en) Proteins producing an altered immunogenic response and methods of making and using the same
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
CY1119106T1 (en) ANTIBODIES AGAINST MASP-2
EP1586649A3 (en) Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP1724282A3 (en) Method for the production of non-immunogenic proteins
HUP9802212A2 (en) Recombinant anti-cd4 antibodies for human therapy
WO2005010151A3 (en) Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP1077719A4 (en) Vaccine delivery system
WO2004110472A3 (en) Fusion proteins
ATE380822T1 (en) FIVE-HELIX PROTEIN
WO2002082041A3 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
WO2001034646A3 (en) Recombinant gelatins
WO2000056901A3 (en) Linear and circular expression elements
BRPI0013885B8 (en) improved pills
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DK1530637T3 (en) Carlsberg subtilisin proteins with reduced immunogenicity
AU2002221908A1 (en) Novel use of protein hydrolysates
WO2003025019A8 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
AU2002237646A1 (en) Production and use of proteins producing an altered immunogenic response
AU2002309259A1 (en) Improved polysaccharide and glycoconjugate vaccines_____________
SI1456238T1 (en) Production of f(ab')2 fragments in mammalian cells
WO2004031354A3 (en) Human sarcoma-associated antigens
NO20020329L (en) Antitumor antibodies, proteins and their use
WO2005066203A3 (en) Targeted immunogens